spacer
home > ebr > winter 2002 > opinion - as 2002 closes and a new year begins
PUBLICATIONS
European Biopharmaceutical Review

Opinion - As 2002 closes and a new year begins

As 2002 closes and a new year begins, these are indeed interesting times for the global biotech industry. Large pharmaceutical players, variously reeling from generic competition battles and regulatory setbacks, appear to be clamouring for the accolade of 'partner of choice' for ideally later, but increasingly earlier stage, quality biotech deals. One thing's for sure: there's value to be had out there at the moment. The only trouble is we are not making the most of it. Pharma companies are increasingly struggling to apply their resources (especially due diligence) to the right deals in anything like a timely manner. The VC community is battling to maintain value in existing portfolios for as long as it takes - and in the face of an IPO window so shut that a ray of light (such as a real product success) is about as likely as a lack of rain in London!


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Helen Abbott, Senior Consultant at Technomark Consulting Services and EBR's Editor
spacer
Dr Helen Abbott
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

CPhI expert forecasts ‘huge growth in Middle East manufacturing with Europe a medium-term target’

CPhI Middle East & Africa (CPhI MEA) expert Madhukar Tanna, Chief Executive Officer of Pharmax, a United Arab Emirates (UAE) based branded generic manufacturer, says favourable conditions in the UAE are resulting in a boom of pharmaceutical manufacturing throughout the region. Government incentive schemes to increase domestic production, coupled with a brand friendly environment and rising healthcare needs is fuelling surging demand – with many new companies and plants launching in the last two years alone.
More info >>

White Papers

pAVEway™ expression system for the efficient expression of therapeutic proteins

Fujifilm Diosynth Biotechnologies

One of the major bottlenecks in the production of biopharmaceuticals is the efficient expression of therapeutic proteins in microbial or mammalian cells. The Escherichia coli pAVEway™ expression system described here has been developed to ensure high product titres and efficient scale up to GMP manufacture, whilst minimising many common issues seen in other expression systems, such as ‘leaky’ expression (expression of recombinant protein in the absence of inducer).
More info >>

 
Industry Events

DIA 2019 Global Annual Meeting

23-27 June 2019, San Diego Convention Center

DIA 2019 is more than just a meeting: it’s where brilliant minds come together to create solutions. Thousands of global innovators will convene to engage in discussions on today’s hottest topics in the life sciences field, propose ways to combat daily challenges, and network to create lasting connections.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement